1. Home
  2. OPTX vs TRDA Comparison

OPTX vs TRDA Comparison

Compare OPTX & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Syntec Optics Holdings Inc.

OPTX

Syntec Optics Holdings Inc.

HOLD

Current Price

$9.68

Market Cap

261.0M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$7.09

Market Cap

274.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OPTX
TRDA
Founded
1981
2016
Country
United States
United States
Employees
159
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
261.0M
274.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
OPTX
TRDA
Price
$9.68
$7.09
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
995.1K
232.5K
Earning Date
03-31-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$4.93
52 Week High
$14.92
$16.45

Technical Indicators

Market Signals
Indicator
OPTX
TRDA
Relative Strength Index (RSI) 43.74 47.10
Support Level $5.93 $5.75
Resistance Level $11.83 $7.19
Average True Range (ATR) 1.67 0.53
MACD -0.41 0.28
Stochastic Oscillator 2.88 66.67

Price Performance

Historical Comparison
OPTX
TRDA

About OPTX Syntec Optics Holdings Inc.

Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: